Language

English

Publication Date

9-1-2025

Journal

Critical Care Explorations Journal

DOI

10.1097/CCE.0000000000001316

PMID

40953288

PMCID

PMC12440467

PubMedCentral® Posted Date

9-15-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Objectives: Guidelines recommend hydrocortisone as an adjunctive treatment in septic shock, but the optimal dosing regimen is unknown. A national shortage of hydrocortisone in 2023 prompted a change in institutional practice for hydrocortisone administration from 50 mg every 6 hours to 100 mg every 12 hours in an effort to reduce waste and conserve vials, creating an opportunity to evaluate the comparative effectiveness of these two regimens. The primary efficacy outcome was time to shock resolution, and secondary outcomes evaluated in this study were mortality, renal replacement therapy (RRT), medication costs, and maximum vasopressor dose attained.

Design: Single-center, retrospective cohort study.

Setting: ICUs in a quaternary academic medical center.

Patients: Adult patients admitted to an ICU with septic shock, defined by mean arterial pressure less than 65 mm Hg despite adequate fluid resuscitation and need for vasopressor infusion, who were treated with hydrocortisone for shock between October 24, 2022, and October 12, 2023.

Interventions: Treatment with hydrocortisone 50 mg every 6 hours or 100 mg every 12 hours.

Measurements and main results: One hundred thirty-eight patients were included in this retrospective chart review from October 24, 2022, to October 12, 2023. Data for 61 patients in the 50 mg every 6 hours group and 77 patients in the 100 mg every 12 hours group were collected and analyzed. In adjusted competing risk models, hydrocortisone regimen was not associated with differences in time to shock resolution (sub-hazard ratio [sub-HR] 0.95 [95% CI, 0.59-1.54]), ICU mortality (sub-HR 1.59; 95% CI, 0.89-2.84), in-hospital mortality (1.35; 95% CI, 0.81-2.26), or time to RRT (sub-HR 1.01; 95% CI, 0.45-2.31). In addition, the hydrocortisone dose regimen was not associated with differences in maximum vasopressor dose attained (mean difference in norepinephrine equivalent, 0.16 µg/kg/min; 95% CI, -0.26 to 0.58 µg/kg/min). The less frequent dosing resulted in cost savings of $446.10 (95% CI, 253.95-638.25) per patient treated with the more intensive but less frequent hydrocortisone dosing regimen.

Conclusions: A less frequent hydrocortisone dosing regimen was not associated with differences in time to shock resolution. Studies of the comparative effectiveness of different corticosteroid dosing regimens for septic shock are needed.

Keywords

Humans, Shock, Septic, Hydrocortisone, Retrospective Studies, Male, Female, Middle Aged, Vasoconstrictor Agents, Aged, Intensive Care Units, Renal Replacement Therapy, Anti-Inflammatory Agents, Treatment Outcome, Dose-Response Relationship, Drug, Drug Administration Schedule, Hospital Mortality, adrenal insufficiency, corticosteroid, hydrocortisone, Septic, shock

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.